Table 1.

Patient and tumor characteristics

Patient ID	Age at primary diagnosis (years)	Tumor size (mm)	Lymph node status (positive/total)	Distant metastasis at diagnosis	ER status	PR status	HER2 status	Nottingham Histological Grade	Time to recurrence (months)	Time to last follow-up or deathb (months)
EM1	42	33	0/2	No	Positive	Positive	Negative	3	20.0	29.4b
EM2	57	28	1/17	No	Positive	Positive	Negative	2	40.0	55.2b
EM3	78	20	6/17	No	Positive	Positive	Negative	3	16.1	17.9b
EM4	34	28	0/2	No	Positive	Positive	Negative	2	31.8	99.0
EM5	61	12	0/5	No	Positive	Positive	Negative	1	48.8	97.1b
EM6	62	Right: 28	2/13	No	Positive	Positive	Negative	2	61.3	87.3
		Left: 55	1/12		Positive	Positive	Negative	3
EM7	55	22	0/2	No	Positive	Negative	Amplified	2	18.9	59.3b
EM8	67	22	2/12	No	Positive	Negative	Negative	2	13.9	33.2b
EM9	50	18	0/1	No	Positive	Positive	Negative	3	36.0	54.7b
EM10	64	45	1/14	No	Positive	Negative	Negativea	2	17.7	33.2b
EM11	59	20	16/18	No	Positive	Positive	Negativea	3	13.9	32.5b
EM12	53	37	4/10	No	Positive	Positive	Negative	2	16.2	33.5b
EM13	69	25	0/4	No	Positive	Negative	Negativea	2	43.9	58.7b
EM14	47	19	1/18	No	Negative	Positive	Amplified	2	20.0	46.7b
DF1	58	15	0/2	No	Positive	Positive	Negative	3		108.7
DF2	37	20	0/3	No	Positive	Positive	Negative	3		111.7
DF3	56	19	0/1	No	Positive	Positive	Negativea	2		109.9
DF4	46	13	0/1	No	Negative	Negative	Negativea	2		110.4
DF5	54	15	0/2	No	Positive	Positive	Negativea	3		109.5
DF6	58	18	0/2	No	Positive	Negative	Negativea	2		113.2

All patients analyzed are women.

^aClinical HER2 analysis not performed. HER2 status determined from gene copy number derived from whole-genome sequencing results.

^bTime from primary diagnosis to death.